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Abstract
Fanconi anemia (FA) is a DNA repair disorder resulting from mutations in genes encoding for FA DNA repair complex
components and is characterized by variable congenital abnormalities, bone marrow failure (BMF), and high incidences of
malignancies. FAmosaicism arises from reversion or other compensatorymutations in hematopoietic cells and may be associated
with BMF reversal and decreased blood cell sensitivity to DNA-damaging agents (clastogens); this sensitivity is a phenotypic and
diagnostic hallmark of FA. Uncertainty regarding the clinical significance of FA mosaicism persists; in some cases, patients have
survived multiple decades without BMF or hematologic malignancy, and in others hematologic failure occurred despite the
presence of clastogen-resistant cell populations. Assessment of mosaicism is further complicated because clinical evaluation is
frequently based on clastogen resistance in lymphocytes, which may arise from reversion events both in lymphoid-specific
lineages and in more pluripotent hematopoietic stem/progenitor cells (HSPCs). In this review, we describe diagnostic methods
and outcomes in published mosaicism series, including the substantial intervals (1–6 years) over which blood counts normalized,
and the relatively favorable clinical course in cases where clastogen resistance was demonstrated in bonemarrow progenitors.We
also analyzed published FA mosaic cases with emphasis on long-term clinical outcomes when blood count normalization was
identified. Blood count normalization in FA mosaicism likely arises from reversion events in long-term primitive HSPCs and is
associated with low incidences of BMF or hematologic malignancy. These observations have ramifications for current investi-
gational therapeutic programs in FA intended to enable gene correction in long-term repopulating HSPCs.
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Fanconi anemia and mosaicism
Fanconi anemia overview
Fanconi anemia (FA) is a deoxyribonucleic acid (DNA) repair
disorder resulting from mutations in genes encoding for
protein components of the FA/BRCA DNA repair pathway.
More than 20 identified proteins interact as components of the
FA core, FANCI, FANCD2 and downstream complexes. In
conjunction with other DNA repair elements, FA proteins
facilitate repair of interstrand crosslinks (ICLs) and other
forms of DNA damage [1, 2]. FA proteins also contribute to
other cellular processes beyond DNA repair, including
cellular responses to oxidative stress and inflammatory
stimuli [3–5].
FA is characterized by frequent bone marrow failure
(BMF), myeloid malignancies, and epithelial cancers [1, 6].
The BMF and neoplastic manifestations of FA are frequently
but not universally accompanied by congenital abnormalities
including growth retardation/short stature, microcephaly, and
abnormalities of skin pigmentation, upper limbs (especially
thumbs and radii), gonads, kidneys, and other organ systems.
Manifestations of BMF are frequently noted during the first
decade of life; the incidences of myeloid and solid organ
malignancies increase during the second and third decades of
life, respectively, such that the cumulative incidence of acute
myeloid leukemia (AML)/myelodysplastic syndrome (MDS)
is approximately 30% by age 30 and the cumulative incidence
of solid organ cancers approaches 40% by age 40 [6, 7].
Fanconi anemia mosaicism
Somatic mosaicism in FA (hereafter referred to as mosaicism)
arises from reversion or other compensatory mutations in hema-
topoietic stem cell/progenitor cells (HSPCs) from which arise a
population of bone marrow and blood cells with a functional
DNA repair capacity. Patients in whom a reversion in a
pathogenic FA mutation has occurred frequently have two
distinct blood cell populations. One population is sensitive to
DNA-damaging agents (mitomycin-C [MMC] or
diepoxybutane [DEB]) and consistent with an FA diagnosis and
another population resistant to these DNA-damaging (or
clastogenic) agents – hence the “mosaic” label indicating the
coexistence of phenotypically distinct cellular components
[8–10]. The purpose of this review is to summarize the existing
literature regarding FA mosaicism, with particular emphasis on
persistent diagnostic and prognostic uncertainties. We provide an
evaluation of case series in which FA mosaic patients were
followed clinically over years (and at times decades), with
emphasis on the clinicopathologic relevance of laboratory
diagnostic evaluations of these cases. Additionally, we
conducted a literature-based assessment of FA mosaic cases
most likely emanating from reversion or other compensatory
mutations in long-term repopulating HSC populations.
Mosaicism in FA patients was noted prior to initial identi-
fication of the first FANC gene (FANCC) in 1992 [11], with
initial reports describing FA patients in whom 60–80% of
cultured lymphocytes (either PHA-stimulated T cells or
EBV-transformed B cells) displayed resistance to
concentrations of alkylating agents typically toxic to FA
patient cells [12, 13]. Several mechanisms by which an
additional genetic event may result in a functional FA gene
and protein have been identified and include gene conversion,
intragenic crossover, back mutation, and second-site mutation
– each of which may result in a restoration of the affected gene
to wildtype [8, 14, 15]. Second-site mutations involve either a
compensatory point mutation (insertion or deletion) at a dis-
tinct site within a mutated gene, resulting in a functional gene
and protein that may be nonetheless distinct from wildtype
[15–17]. The mechanisms by which these various mutations
may result in cell populations expressing a functional gene
and/or protein are illustrated in Fig. 1.
Mosaicism in other genetic disorders
Reversion mutations and resultant mosaicism have been
reported in Bloom syndrome, X-linked and adenosine
deaminase severe combined immunodeficiency (X-SCID and
ADA-SCID), Diamond Blackfan anemia (DBA), Wiskott-
Aldrich syndrome, epidermolysis bullosa, tyrosinemia, and
dyskeratosis congenita (DC) [18–25]. The extent of
phenotypic correction in any clinical setting is dependent on
both the chronology of a reversion event either during
embryonic or postnatal development and the degree by which
a disorder manifests in hierarchical (as opposed to heterarchical)
organ systems. Disorders predominantly affecting blood cells
may be particularly reversible because of the hierarchical
nature of hematopoiesis, with partial or comprehensive
phenotypic corrections identified most frequently in the
context of normalization within a single lineage [19–21].
Multilineage mosaicism has been reported in DC [25]. In
several of these conditions and in FA in particular, the
underlying disorder predisposes to heightened genetic
instability, enhancing the potential for additional mutations,
many of which are potentially deleterious (resulting in
characteristic frequent malignancy in Bloom syndrome, DBA,
DC, and FA), but in more limited instances may confer a
beneficial phenotypic reversion. A particularly unstable
intragenic duplication was recently characterized in a FANCB
patient with mosaicism associated with mild hematologic
deficits. The instability of this duplication was evident not
only from a decreasing percentage of aberrant blood cells over
11 years of observation but from the presence of a modest
population (8%) of fibroblasts displaying a wild-type allele,
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representing the first identification of reversion in a non-
hematopoietic cell population in FA [26].
FA mosaicism: selective growth advantage
and prognostic uncertainty
In the abovementioned diseases, mosaicism has been de-
scribed as “natural gene therapy” [27, 28], and a selective
growth advantage of revertant cells in selected disorders and
organ systems (including the hematologic component of FA)
has long been hypothesized. The potential for a marked
proliferative advantage at the HSC level has been most
profoundly illustrated by a case of monozygotic twin sisters
diagnosed with FA early in life who nonetheless had
demonstrated hematologic stability during 28 years of
reported follow-up, with clastogen resistance evident in
peripheral blood lymphocytes despite characteristic fragility
of cultured fibroblasts. Analysis of bone marrow progenitors
indicated multilineage presence of the compensatory
mutation, consistent with a hypothesized prenatal reversion
in a long-term HSC, resulting in multilineage engraftment
via shared in utero circulation [28, 29]. This example of gene
reversion and selective growth advantage enabling compre-
hensive and sustained hematopoiesis has represented a natu-
rally occurring proof of concept for the potential hematologic
correction of FA via gene therapy. A selective advantage of
gene-corrected FA cells has been demonstrated in murine FA
models [30–32], human embryonic stem cells [33], induced
pluripotent stem cells [34], and gene-corrected cells from FA
patients transplanted in immunocompromised mice [35];
these observed in vivo selective advantages have been largely
facilitated by administration of cytotoxic conditioning agents.
A selective advantage has also recently been demonstrated in
nonconditioned FA-A patients receiving gene-corrected
Fig. 1 Several mechanisms by which additional chromosomal
rearrangements or mutations may facilitate correction of an inherited
recessive genetic disorder. The yellow and blue bars indicate an
individual gene, with black hashes indicating a disease-causing
mutation. Reversion mutations may arise either during or subsequent to
DNA replication and may involve transfer of genetic material between
paired chromosomes (gene conversion or intragenic crossover) or
mutations within a single chromosome (and gene). Gene conversion,
intragenic crossover, and back mutations result in genetic correction in
one allele within a daughter cell (indicated by the green border and
background). Second-site mutations (white hash) result in a gene
capable of generating a functional protein (indicated by the green
dashed border and green background) in one allele, although the gene
itself may differ from wildtype. Adapted from Pasmooij et al. [17]
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autologous CD34+ cells, by means of progressive increases in
gene-corrected and clastogen-resistant lymphocytes and mar-
row progenitors during 18–30 months of follow-up [36].
The presence of a revertant FA hematopoietic cell popula-
tion has often been associated with a favorable hematologic
course in FA patients. However, the presence of clastogen-
resistant blood and marrow cells may not uniformly be asso-
ciated with long-term BMF- or AML-free survival. Gregory
and colleagues reported a male patient with hematologic sta-
bility during the initial 9–17 years of life and a stable popula-
tion of DEB-resistant peripheral blood lymphocytes (61–
74%). Analysis of bone marrow progenitors at age 15 indicat-
ed multilineage presence of the revertant mutation (including
lymphoid, myeloid, and erythroid progenitors). At ages 15
and 17, this patient nonetheless developed evidence of an
11q deletion in a population of non-revertant bone marrow
cells – a cytogenetic abnormality potentially associated with
myeloid malignancy [37]. The prognostic uncertainty regard-
ing the presence of a hematopoietic population containing a
reversion mutation is rendered additionally complex because
the diagnostic methods utilized in FA are most frequently
directed at a differentiated T-lymphoid cell population that
may be genetically divergent from multilineage stem and pro-
genitor populations. The diagnosis and clinical prognosis of
FA mosaic patients during recent decades are detailed
subsequently.
Mosaicism diagnosis
Diagnosis of mosaicism in FA is contingent on demonstration
of a population of blood and/or bone marrow cells that display
resistance to concentrations of DNA-damaging agents that are
typically toxic to FA hematopoietic cells. Diagnostic challenges
persist because mosaicism may be restricted to specific cell
lineages and evaluation of multiple blood and marrow lineages
is frequently not clinically feasible. The percentage of resistant
cells within a single lineage may not be indicative of the overall
hematologic milieu and (especially at a single timepoint) may
not provide clinically meaningful prognostic information.
A critical component of an FA diagnosis and of potential
FA mosaicism involves evaluation of cultured T lymphocytes
in the presence of DNA-damaging agents, most frequently
DEB or MMC. Lymphocytes from FA patients frequently
display marked chromosomal instability (also referred to as
fragility, evidenced by chromosomal breaks and radial fig-
ures) in the presence of clastogen concentrations that result
in minimal abnormalities in non-FA cells [9, 10]. Some cen-
ters, including those involved in the evaluation of a large and
rigorously followed Spanish FA mosaic population, have pro-
posed diagnostic algorithms classifying individuals with few-
er than 20% aberrant cells cultured in 0.1-μg/ml DEB as non-
FA patients, 20–40% as consistent with FAmosaics, > 60% as
consistent with FA, and 40–60% as possible mosaicism, with
additional information regarding the number of breaks per cell
further contributing to diagnosis [10]. Specific DNA-
damaging agents, concentrations, other culture and cell selec-
tion conditions, and threshold aberrancy levels have varied
among investigative centers such that no single standard for
a determination of mosaicism exists. The presence of diver-
gent DEB resistance between a patient’s lymphocytes and
cultured fibroblasts is considered consistent with FA mosai-
cism, as is an increasing percentage of DEB-resistant lympho-
cytes over sequential intervals. A German-led international
consortium of investigative centers has also identified mosai-
cism by decreased clastogen stimulation of G2-phase arrest
[15]; French investigators have described normalized
FANCD2 ubiquitination in the presence of clastogens as in-
dicative ofmosaicism [38]. As will be discussed subsequently,
results of DEB-chromosomal stability evaluations in periph-
eral blood lymphocytes may not necessarily be indicative of
reversions in other hematopoietic compartments, including
multipotent HSPCs [14].
Gene sequencing has become an increasingly valuable and
utilized modality for the confirmation of an FA diagnosis;
however, sequencing of distinct blood and marrow progenitor
cell populations has been performed infrequently and con-
tinues to be a predominantly research-focused modality [28,
37]. Evaluation of the MMC resistance of cultured bone
marrow-derived colony forming cells (CFCs) has emerged
as a complementary test for identifying phenotypic reversion
in progenitor populations. The number of investigations in
which this parameter has been correlated with long-term clin-
ical outcomes is extremely limited [28, 37, 39]; however, the
increasing percentage of MMC-resistant bone marrow CFCs
has been identified in recent autologous gene therapy clinical
trials and has been recognized as a relevant indicator of genet-
ic and phenotypic reversal in pluripotent hematopoietic pro-
genitor cells [36]. Ongoing discussions involving internation-
al multidisciplinary investigators have increasingly identified
MMC resistance of bone marrow progenitors as meaningful
and potentially objective clinical phenomena in either FA mo-
saicism or autologous hematopoietic gene therapy settings
[40, 41]. Ongoing consensus discussions have also indicated
the potential importance of evaluations employing multiple
MMC concentrations, serial evaluations of MMC resistance
over time, and corroboration of clastogen resistancewith func-
tional assays such as FANCD2 ubiquitination. When feasible,
genetic sequencing and multilineage assessment are addition-
ally relevant for comprehensive mosaicism assessment.
Clinical outcomes in FA mosaic patients
In addition to the two illustrative and deeply investigated FA
mosaic cases described previously, several additional series
published over a 16-year period (1997–2013) have detailed
the clinical course and essential laboratory correlates in FA
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mosaic patients. These include 4 publications and a published
doctoral thesis, describing outcomes in FA mosaic patients
(range: n = 5–14 per publication) [8, 14, 15, 38, 39].
Detailed information regarding these series is provided in
Table 1. Essential themes emerging from these cohorts include
the following:
1. FA mosaicism has largely been reported in cases arising
from more frequently observed mutations in FA core and
ubiquitination complex genes (predominantly FANCA,
FANCC, and FANCD2); there is limited published infor-
mation on FAmosaicism arising frommutations in down-
stream or more recently discovered FA genes/proteins
[26, 42, 43].
2. Hematologic stability and improvement have been noted
in a single lineage, or frequently in bi- and trilineage set-
tings, consistent with the hypothesis that reversion muta-
tions arise across a spectrum of pluripotent or more com-
mitted HSPCs [39].
3. A broad range of peripheral blood lymphocyte resistance
to DEB (or other clastogens) has been reported, with a
limited number of studies showing correlation between
the percentages of resistant PB cells and clinical out-
comes. (Of note, T lymphocyte mosaicism has been re-
ported in up to 15–20% of FA patients and had been
frequently associated with HSCT engraftment failure pri-
or to the incorporation of fludarabine-based conditioning)
[44].
4. FA mosaicism has been frequently but not universally
associated with stable or increasing hematologic parame-
ters over prolonged follow-up.
5. In the limited settings where normalization of blood
counts has been observed over time, increases in blood
lineages have been reported over a 1- to 6-year interval
(most frequently over 2–3 years), and multilineage in-
creases have been observed in non-contemporaneous
(i.e., staggered) sequences as indicated in Table 1 [14,
38, 39].
6. In the limited settings where normalization of blood
counts has been observed over time, platelet normaliza-
tion has at times been the most indolent and incomplete
relative to other lineages, with some increases resulting in
levels below normal limits but not requiring clinical inter-
vention, as indicated in Table 1 [14, 39].
7. Evaluation of MMC resistance in bone marrow CFCs has
been undertaken infrequently. In the one series in which
BM MMC resistance was evaluated, 5 of 5 patients with
documented MMC resistance were alive and without he-
matologic complications at last follow-up (with stable
clinical course over 9–15 years in 3 patients for whom
this information was available) and 2 of 4 patients in
whom marrow CFCs were sensitive to MMC died at ages
11 and 18 of BMF and unspecified complications [39].
An additional investigation based on these and other pub-
lished FA mosaic cases is described in a subsequent section of
this review. We undertook this literature-based investigation
with an intent of identifying a subset of FA mosaic patients
most likely to harbor reversion mutations in long-term
repopulating HSCs.
Hypomorphic mutations in FA
Relatively little has been reported regarding the incidence or
clinical significance of hypomorphic mutations in FA, in
which the impacted protein is expressed with reduced quantity
and/or function. Hypomorphic mutations have been described
in FANCD2 and were not associated with any reduction in the
typically aggressive hematologic manifestations associated
with this complementation group; the incidence of mosaicism
in FANCD2 also appears comparable to that in FANCA or
other core complex FA groups [15].
Recently, a cohort of 11 Sicilian patients with FANCA
hypomorphic mutations were reported, in which mutations
resulted in FANCA proteins that localized to cytoplasm and
facilitated more normalized mitochondrial function (relative
to cells lacking FANCA), with peripheral blood-derived lym-
phoblast sensitivity comparable to non-mosaic FA patients.
The clinical course of this cohort ranged from indolent (n =
3) to severe (n = 2), with the majority of patients (n = 6) en-
countering moderate single-, bi-, or trilineage cytopenias and
receiving allogeneic hematopoietic transplant at ages 9–21
[45]. It is likely that as more comprehensive genetic sequenc-
ing becomes clinically feasible, additional hypomorphic mu-
tations may be recognized, including some with potential for
more indolent clinical progression resemblant of mosaicism,
but without the clastogen resistance associated with compen-
satory mutations in FA. Additional investigations into the mi-
tochondrial and other “non-canonical” functions of FA pro-
teins may also elucidate potential prognoses associated with
these uncommon variants [46].
Review of FA mosaic publications
with emphasis on blood count normalization
Overview and objectives
The clinical significance of FA mosaicism remains uncertain
more than 20 years after this phenomenon was initially report-
ed. We sought a comprehensive literature-based understand-
ing of FA mosaicism with emphasis on cases most likely em-
anating from reversion mutations in long-term repopulating
HSC populations. Focusing on the minority of FA mosaic
cases in which normalization of all peripheral blood lineages
was reported, we identified a population of FAmosaic patients
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in whom there appears to be high likelihood of multi-decade
BMF-free and leukemia-free survival.
Our objectives were to identify FAmosaicism cases report-
ed in the medical literature for which there was information
regarding individual patient clinical outcomes and to further
identify the subset of FA mosaic cases in which there was
normalization of all peripheral blood lineages (because such
cases likely result from reversion mutations in long-term
repopulating HSC populations) and to determine clinical
course in this clinical subpopulation. In particular, we sought
to quantify the incidences of BMF, hematologic malignancy,
and other adverse outcomes in FA mosaic patients, including
those with blood count normalization and those with no or
incomplete normalization.
Methods
We identified published FA mosaic cases via PubMed
searches, reference citations, and a publicly available doctoral
thesis on this specific condition. A database was constructed
from cases in which there was sufficient clinical information
enabling evaluation of age at FA and mosaic diagnosis, dura-
tion of follow-up and development of BMF, malignancy, al-
logeneic hematopoietic stem cell transplant (HSCT), survival,
and cause of death. Blood count normalization was defined as
improvement in absolute neutrophil count (ANC) to at least
1000/mm3, hemoglobin to at least 9 g/dL, and platelets to at
least 50,000/mm3 after previously lower levels or
maintenance of these levels over multiple intervals in settings
where earlier counts were not available or presence of these
levels at a single timepoint with prior/subsequent hematologic
stability reported by the investigator or blood counts normal-
ized or within normal range per investigator without precise
values specified.
Results
Figure 2 details the literature search results in which 51 pub-
lications describing FA mosaicism were identified between
1976 and 2018, of which 23 publications (n = 123 patients)
contained clinical information. A subset of 37 patients (30%)
had normalization of blood counts (including 19 for whom
detailed blood count information over multiple timepoints
was reported). Fifteen FA mosaic patients were reported in
whom no or incomplete normalization (including normaliza-
tion of 1 or 2 lineages) was described. Blood count informa-
tion was not reported in 71 patients. The subgroup of 37 FA
mosaic patients with normalized blood counts were reported
from investigators in Spain (n = 13), Germany (n = 10),
France (n = 8), the USA (n = 5), and Japan (n = 1).
Complementation groups of patients in this cohort were
Group A (n = 24), Group B (n = 1), Group C (n = 1), Group
E (n = 1), Group T (n = 1), and not reported/known (n = 9).
Publications detailing these patients are shown in
Supplemental Table 1. As indicated previously, there is limit-
ed published information on FA mosaicism arising from
Fig. 2 In the cohort of FAmosaic patients (n = 37) with normalized blood
counts and information regarding clinical outcomes, individuals were
included from the following cohorts: Spain (n = 13), Germany (n = 10),
France (n = 8), the USA (n = 5), and Japan (n = 1). Complementation
groups of patients identified in this cohort included: Group A (n = 24),
Group B (n = 1), Group C (n = 1), Group E (n = 1), and Group T (n = 1);
in n = 7 patients, complementation group was unknown
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mutations in downstream or more recently discovered FA
genes/proteins.
The clinical outcomes for the 37 FA mosaic patients with
normalized blood counts are depicted in Fig. 3. Median
follow-up within this subgroup was to age 18 (range 4–
34 years). Thirty-four patients (92%) were alive at last fol-
low-up. Death in 3 patients occurred at ages 19 (AML), 29
(lung cancer), and 29 (head and neck cancer). BMF was re-
ported in one patient (3%, age 20) and leukemia (AML/MDS)
in one patient (3%, age 19). An additional patient developed
an 11q deletion (MLL rearrangement) in a clonal population
persistent over 2 years of follow-up but without overt evi-
dence of leukemia. Solid organ malignancies were reported
in 4 patients (11%, ages 24–33) including 2 patients with
Fig. 3 Swimmer plot depicting clinical course for 37 FA mosaic patients
with normalized blood counts, including age at diagnosis (when
available), last follow-up, and occurrences of BMF, AML/MDS,
allogeneic HSCT, and solid organ cancers. The majority of patients (34
of 37) were alive without BMF, malignancy, or transplant at last follow-
up. Criteria for normalization are provided in the text and are in general
more stringent (exclusive) than those applied by investigators in Table 1
Table 2 Clinical outcomes for
Fanconi anemia mosaic patients A. Mosaic with blood count normalization (n = 37)
Status n (%) Age (y)
Alive at last follow-up 34 (92%) At last follow-up: Median: 18 Range: 4–34
Deceased at follow-up 3 (9%) At death: 19, 29, 29
BMF 1 (3%) At BMF diagnosis: 20
AML/MDS 1 (3%) At AML/MDS diagnosis: 19
Solid organ malignancy 4 (11%) At cancer diagnosis: Median: 29 Range: 24–33
B. Mosaic with no/incomplete blood count normalization (n = 15)
Status n (%) Age (y)
Alive at last follow-up 8 (53%) At last follow-up: Median:14 Range: 8–47.5
Deceased at follow-up 7 (47%) At death: Range: 9–39
BMF 12 (80%) At BMF diagnosis: Median: 9.5 Range: 0–47.5
AML/MDS 2 (13%) At AML/MDS diagnosis: 17.5, 47.5
Solid organ malignancy 2 (13%) At cancer diagnosis: 38, 39
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multiple sequential cancer diagnoses. Additional details re-
garding these outcomes are provided in Table 2. The clinical
outcomes for the 15 FA mosaic patients in whom no or in-
complete normalization was reported were more adverse and
are provided in Table 2; 8 of these patients (53%) were alive at
last follow-up with 7 deaths occurring between ages 9 and 39.
BMF was reported in 12 of 15 patients (80%, median age
9.5 years); 2 of 15 patients (13%) developed AML/MDS,
and 2 (13%) developed solid organ malignancies.
FA mosaic patients with blood count normalization were
less likely to develop BMF (p < 0.0001, Fisher’s Exact Test, 2-
sided) and more likely to remain alive (p = 0.0034) relative to
FA mosaics without normalization. A lower percentage of
mosaic patients with normalization developed hematologic
malignancy (3% vs. 14%), but this difference was not statis-
tically significant. The incidences of solid organ malignancies
were similar between these subgroups.
Based on these findings, FA mosaicism with normalized
blood counts appears to occur in a minority (30%) of patients
whose peripheral lymphocyte assessments indicate resistance
to DNA-damaging agents via standard testing; the potential
for reporting bias is such that the actual incidence may be
lower; it is likely that fewer than 5% of all FA patients expe-
rience blood count normalization as a result of reversion/
compensatory mutations. FA mosaicism with normalized
blood counts is associated with very limited incidences of
BMF or hematologic malignancy, limited requirement for al-
logeneic HSCT, and relatively limited mortality during the
initial 2–4 decades of life. Solid tumors arise during the 3rd
and 4th decades of life in FA mosaic patients regardless of
blood count normalization, as is the case with non-mosaic
FA patients. Two of four FA patients with normalized blood
counts who developed solid tumors had a second malignancy
diagnosed within several years of the initial cancer diagnosis;
solid tumors were fatal in at least 2 of 4 reported patients.
Discussions and summary
These findings indicate that there is a population of FAmosaic
patients with very limited risk of BMF or hematologic malig-
nancy, likely as a result of reversion mutations in primitive
HSPC populations. Limitations for conclusive analysis result
from the absence of bone marrow-based genetic or
mitomycin-resistance evaluation in the overwhelming major-
ity of FA mosaic cases. Analysis is also limited because se-
quential chronologic assessment of peripheral blood or bone
marrow clastogen resistance has been performed infrequently.
It is very likely that FA mosaicism with normalized blood
counts is the result of mutations in long-term HSPCs, but it
is not known what percentage of HSPC with reversion events
is required to enable stable or normalized peripheral blood cell
counts [28, 37]. Presumably those mosaic patients in whom
no or incomplete normalization occurred were diagnosed as a
result of reversions in committed progenitor (lymphoid-
inclusive) lineage or short-term repopulating progenitor cells,
but more detailed genetic evaluation of progenitor lineages
will be needed to validate this hypothesis. Additional nonge-
netic elements (including epigenetic factors, stromal microen-
vironment, telomeric depletion, and aldehyde exposure and
metabolism) may also contribute to hematopoietic stability
in settings of genetic correction [5, 47, 48]. It is plausible that
reversion events may only result in favorable clinical out-
comes when these take place in long-term repopulating
HSCs and additional favorable metabolic or other nongenetic
conditions. A case of mosaicism emerging subsequent to ini-
tiation of androgen therapy has been reported, with blood
count normalization persisting subsequent to androgen dis-
continuation (duration undetermined); it is plausible that an-
drogens may selectively enhance hematopoiesis in dormant
revertant HSCs and that some cases of prolonged androgen-
attributed hematologic benefit were in fact the result of unde-
tected mosaicism [49]. Prospective translational studies will
be required to enable optimal understanding of genotype/
phenotype correlations in settings of reversion mutations or
therapeutic genetic correction – these are planned in the con-
text of the next generation of gene therapy clinical
investigations.
Clinical trials of autologous gene therapy in FA have been
conducted during the prior decades, with most recent results
indicating genetic correction and reversal of sensitivity to
DNA-damaging agents at levels resembling those seen in FA
mosaic patients [35, 50, 51]. Our findings also provide ratio-
nale for further clinical evaluation of gene therapy because
they indicate that there is a likely threshold of genetic and
phenotypic correction above which multi-decade BMF-free
survival may be likely. These comparisons between FA mo-
saic and gene therapy treated patients are limited in that mo-
saicism likely results from a single-cell mutation (or mutation
within a very finite subset of cells), whereas gene therapy
involves introduction of a likely higher number of gene-
corrected HSPCs with oligoclonal hematopoietic repopulation
observed to date [36]. The long-term significance of the
oligoclonal hematopoiesis identified in nonconditioned gene
therapy recipients (and suspected in FA mosaic patients) is
uncertain, although there exist similarities to the clonal hema-
topoiesis that has become increasingly recognized as a distinct
phenomenon, particularly in elderly individuals. Clonal hema-
topoiesis in the elderly occurs frequently and, even in the
absence of mutations identified with hematologic malignancy,
is associated with increased risk of hematologic malignancy
and cardiovascular events, although the absolute risk in indi-
vidual patients is relatively limited [52, 53]. Long-term fol-
low-up studies of the initial gene therapy treated FA patients
are underway, although multi-year observation will likely be
required to enable definitive conclusions regarding the rami-
fications of oligoclonal hematopoiesis.
Ann Hematol (2020) 99:913–924 921
In summary, FA mosaicism is a condition in which varied
and frequently divergent degrees of resistance to DNA dam-
age are present within the hematopoietic system of an individ-
ual patient, or (more rarely) the entire hematopoietic system
displays evidence of normal or near-normal resistance to DNA
damage despite clastogen sensitivity in non-hematopoietic tis-
sues. These findings are at times accompanied by normalized
or stable peripheral blood counts, with some patients surviv-
ing into adulthood without bonemarrow failure or hematolog-
ic malignancy. Some degree of mosaicism is likely present in
15–20% of FA patients, although the incidence of reversion
mutations in primitive HSCs resulting in sustained hematolog-
ic stability likely occurs in fewer than 5% [9, 10, 15, 38]. Our
additional evaluation of 37 cases with documented blood cell
count normalization suggests that there is a population of FA
patients in whom a sufficient genetic reversion and selective
advantage enable hematologic stability through at least three
decades with limited BMF or myeloid malignancy. The long-
term results of gene therapy studies – especially those involv-
ing no conditioning – are likely to provide important informa-
tion as to the clinical relevance of reversion mutations and
other forms of genetic correction in this complex disorder.
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